These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30243783)

  • 21. Ramipril and haloperidol as promising approaches in managing rheumatoid arthritis in rats.
    Fahmy Wahba MG; Shehata Messiha BA; Abo-Saif AA
    Eur J Pharmacol; 2015 Oct; 765():307-15. PubMed ID: 26302059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibulin-3 and other cartilage metabolism biomarkers in relationship to calprotectin (MRP8/14) and disease activity in rheumatoid arthritis patients treated with anti-TNF therapy.
    Kopec-Medrek M; Kucharz EJ
    Adv Clin Exp Med; 2018 Mar; 27(3):383-389. PubMed ID: 29533545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rheumatoid factor does not predict response to TNF antagonists in rheumatoid arthritis: three centers experience.
    Salgado E; Campos J; Moreira-Navarrete V; Mulero J; Navarro F; Pérez-Pampín E; Carmona L; Gómez-Reino J
    Joint Bone Spine; 2013 Jul; 80(4):438-40. PubMed ID: 23453477
    [No Abstract]   [Full Text] [Related]  

  • 24. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study.
    Curtis JR; Sarsour K; Napalkov P; Costa LA; Schulman KL
    Arthritis Res Ther; 2015 Nov; 17():319. PubMed ID: 26555431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of Abatacept in Chilean Patients With Long-standing Severe Rheumatoid Arthritis Without Previous Use of Biologics.
    Valenzuela O; Ibáñez S; Poblete MP; Mardones C; Mogollones K; Silva F; Villar MJ
    J Clin Rheumatol; 2019 Oct; 25(7):308-310. PubMed ID: 29596207
    [No Abstract]   [Full Text] [Related]  

  • 27. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
    Gibbons LJ; Hyrich KL
    BioDrugs; 2009; 23(2):111-24. PubMed ID: 19489652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study.
    Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Pavelka K; Chartier M; Poncet C; Rauch C; Le Bars M
    BMC Musculoskelet Disord; 2015 Jul; 16():176. PubMed ID: 26228643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada.
    Weijers L; Baerwald C; Mennini FS; Rodríguez-Heredia JM; Bergman MJ; Choquette D; Herrmann KH; Attinà G; Nappi C; Merino SJ; Patel C; Mtibaa M; Foo J
    Rheumatol Int; 2017 Jul; 37(7):1111-1123. PubMed ID: 28560470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.
    Jones G; Hall S; Bird P; Littlejohn G; Tymms K; Youssef P; Chung E; Barrett R; Button P
    Int J Rheum Dis; 2018 Aug; 21(8):1581-1590. PubMed ID: 29205926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
    Harrold LR; Reed GW; Solomon DH; Curtis JR; Liu M; Greenberg JD; Kremer JM
    Arthritis Res Ther; 2016 Dec; 18(1):280. PubMed ID: 27906048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis.
    Charles-Schoeman C; Gugiu GB; Ge H; Shahbazian A; Lee YY; Wang X; Furst DE; Ranganath VK; Maldonado M; Lee T; Reddy ST
    Atherosclerosis; 2018 Aug; 275():107-114. PubMed ID: 29886354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
    Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
    Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients.
    Shahabi A; Shafrin J; Zhao L; Green S; Curtice T; Marshall A; Paul D
    J Med Econ; 2019 Apr; 22(4):350-358. PubMed ID: 30653389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New therapies for rheumatoid arthritis].
    Salgado E; Maneiro JR
    Med Clin (Barc); 2014 Nov; 143(10):461-6. PubMed ID: 24461738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
    Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
    Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of abatacept in rheumatoid arthritis.
    von Kempis J; Dudler J; Hasler P; Kyburz D; Tyndall A; Zufferey P; Villiger PM
    Swiss Med Wkly; 2012; 142():w13581. PubMed ID: 22581564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept.
    Neubauer AS; Minartz C; Herrmann KH; Baerwald CGO
    Clin Exp Rheumatol; 2018; 36(3):448-454. PubMed ID: 29303709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is abatacept an effective treatment for patients with RA who do not respond to other anti-TNF treatments?
    Taylor PC
    Nat Clin Pract Rheumatol; 2006 Mar; 2(3):128-9. PubMed ID: 16932670
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.